1Tarlatzis BC,Zepiridis L,Grimbizis G,et al.Clinical manage-ment of lowovarian response to stimulation for I VF:a system-atic review[].Human Reproduction Update.2003
4Clowse ME,Behera MA,Anders CK,et al.Ovarian preservation by GnRH agonists during chemotherapy:a meta-analysis[J].J Womens Health(Larchmt),2009,18:311-319.
5Ben-Aharon I,Gafter-Gvili A,Leibovici L,et al.Pharmacological interventions for fertility preservation during chemotherapy:asystematic review and meta-analysis[J].Breast Cancer Res Treat,2010,122:803-811.
6Kim SS,Lee JR,Jee BC,et al.Use of hormonal protection for chemotherapy-induced gonadotoxicity[J].Clin Obstet Gynecol,2010,53:740-752.
7Bedaiwy MA,Abou-Setta AM,Desai N,et al.Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy:a systematic review and meta-analysis[J].Fertil Steril,2011,95:906-914.
8Imai A,Sugiyama M,Furui T,et al.Direct protection by a gonadotropin-releasing hormone analog from doxorubicininduced granulosa cell damage[J].Gynecol Obstet Invest,2007,63:102-106.
9Blumenfeld Z.How to preserve fertility in young women exposed to chemotherapy?The role of GnRH agonist cotreatment in addition to cryopreservation of embrya,oocytes,or ovaries[J].Oncologist,2007,12:1044-1054.
